Title: Liquid Biopsy Market worth 1.66 Billion USD by 2021
1MarketsandMarkets Presents
Liquid Biopsy Market worth 1.66 Billion USD by
2021
http//www.marketsandmarkets.com/Market-Reports/li
quid-biopsy-market-13966350.html
2The report "Liquid Biopsy Market Cancer Type
(Lung, Breast, Colorectal, Prostate, Liver),
Circulating Biomarkers (Circulating Tumor Cells,
Circulating Tumor DNA), Product (Instruments,
Software), End User (Reference Laboratory,
Research Centers) - Forecast to 2021", provides a
detailed overview of the major drivers,
restraints, challenges, opportunities, current
market trends, and strategies impacting the
liquid biopsy market along with the estimates and
forecasts of the revenue. Browse 75 market data
Tables and 74 Figures spread through 160 Pages
and in-depth TOC on "Liquid Biopsy Market Cancer
Type (Lung, Breast, Colorectal, Prostate, Liver),
Circulating Biomarkers (Circulating Tumor Cells,
Circulating Tumor DNA), Product (Instruments,
Software), End User (Reference Laboratory,
Research Centers) - Forecast to
2021" http//www.marketsandmarkets.com/Market-Rep
orts/liquid-biopsy-market-13966350.html
http//www.marketsandmarkets.com/Market-Reports/li
quid-biopsy-market-13966350.html
3 Early buyers will receive 10 customization on
this report.
http//www.marketsandmarkets.com/Market-Reports/li
quid-biopsy-market-13966350.html
4- The liquid biopsy market is expected to reach USD
1.66 Billion by 2021 from USD 0.58 Billion in
2016, growing at a CAGR of 23.4 during this
period. - A number of factors, such as the rising incidence
of cancer, benefits of liquid biopsy over solid
tumor biopsy, technological advancements,
availability of funding, and growing awareness
about liquid biopsy through conferences and
government initiatives, are driving the growth of
the market. However, unclear regulatory and
reimbursement scenario is the major area of
concern in this market.
http//www.marketsandmarkets.com/Market-Reports/li
quid-biopsy-market-13966350.html
5-
- In this report, the liquid biopsy market is
segmented on the basis of cancer type,
circulating biomarkers, products services, end
users, and regions. Based on cancer type, the
market is segmented into lung cancer, breast
cancer, colorectal cancer, prostate cancer, liver
cancer, and other cancers. The other cancers
segment includes melanoma, bladder cancer, and
ovarian cancer. In 2016, the lung cancer segment
is expected to account for the largest share of
the market, followed by breast cancer.
http//www.marketsandmarkets.com/Market-Reports/li
quid-biopsy-market-13966350.html
6- Based on circulating biomarkers, the liquid
biopsy market is categorized into four major
segments, namely, circulating tumor cells (CTCs),
circulating tumor DNA (ctDNA), Extracellular
Vesicles (EVs), and other biomarkers. The other
biomarkers segment includes circulating RNA and
proteins. The circulating tumor cells segment is
expected to account for the largest share of the
global market in 2016, followed by the
circulating tumor DNA segment. Based on products
and services, the market is segmented into
instruments, reagents, and services and software.
http//www.marketsandmarkets.com/Market-Reports/li
quid-biopsy-market-13966350.html
7- Based on end user, the liquid biopsy market is
segmented into reference laboratories,
hospital/physician laboratories, academic and
research centers, and other end users. The other
end-users segment includes public health
laboratories, pathology laboratories, and small
molecular laboratories.
http//www.marketsandmarkets.com/Market-Reports/li
quid-biopsy-market-13966350.html
8- In 2016, North America is expected to account for
the largest share of the global market. The large
share of this regional segment can be attributed
to factors such as easy accessibility and high
adoption of advanced diagnostic technologies,
such as PCR and NGS, among healthcare
professionals increasing prevalence of cancer in
the U.S. and Canada and continuous technological
advancements in liquid biopsy. The Asia-Pacific
market, however, is estimated to witness the
highest growth during the forecast period owing
to the increasing focus of market players on this
region.
http//www.marketsandmarkets.com/Market-Reports/li
quid-biopsy-market-13966350.html
9- Biocept Inc. (U.S.), Myriad Genetics (U.S.),
QIAGEN (Netherlands), Roche (Switzerland),
Bio-Rad Laboratories Inc. (U.S.), Trovagene Inc.
(U.S.), Guardant Health, Inc. (U.S.), Janssen
Diagnostics, LLC (U.S.), Fraunhofer-Gesellschaft
(Germany), and MDxHealth SA (U.S.) are the major
players in the liquid biopsy market.
http//www.marketsandmarkets.com/Market-Reports/li
quid-biopsy-market-13966350.html
10Contact Us
Contact Mr. Rohan Markets and Markets UNIT no
802, Tower no. 7, SEZ Magarpatta city,
Hadapsar Pune, Maharashtra 411013,
India 1-888-600-6441 Email sales_at_marketsandmarket
s.com
http//www.linkedin.com/company/marketsandmarkets
http//www.marketsandmarkets.com/Market-Reports/li
quid-biopsy-market-13966350.html
11About MarketsandMarkets
MarketsandMarkets is the global market research
and consulting company based in the U.S. We
publish strategically analyzed market research
reports and serve as a business intelligence
partner to Fortune 500 companies across the
world. MMs flagship competitive intelligence
and market research platform, "RT" connects over
200,000 markets and entire value chains for
deeper understanding of the unmet insights along
with market sizing and forecasts of niche
markets. The new included chapters on Methodology
and Benchmarking presented with high quality
analytical infographics in our reports gives
complete visibility of how the numbers have been
arrived and defend the accuracy of the
numbers. We at MarketsandMarkets are inspired
to help our clients grow by providing apt
business insight with our huge market
intelligence repository.
http//www.marketsandmarkets.com/Market-Reports/li
quid-biopsy-market-13966350.html